0001004878-16-000346.txt : 20160115 0001004878-16-000346.hdr.sgml : 20160115 20160115165536 ACCESSION NUMBER: 0001004878-16-000346 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160113 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20160115 DATE AS OF CHANGE: 20160115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 161346003 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 8-K 1 form8kitem102prepay1-16.txt FORM 8-K ITEM 1.02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2016 CEL-SCI CORPORATION ---------------------------------- (Exact name of registrant as specified in its charter) Colorado 001-11889 84-0916344 ----------------------- ------------------ ---------------- (State or other jurisdiction (Commission File No.) (IRS Employer of incorporation) Identification No.) 8229 Boone Blvd. #802 Vienna, VA 22182 ----------------------------------------------- (Address of principal executive offices, including Zip Code) Registrant's telephone number, including area code: (703) 506-9460 N/A ----------------------------------------------- (Former name or former address if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14c)) Item 1.02 Termination of a Material Definitive Agreement. As of January 12, 2016 the Company owed the de Clara Trust (the "Trust") $1,105,989, which amount included accrued and unpaid interest. The maturity date of the loan from the Trust was July 6, 2018. Although the Trust could only demand payment prior to July 6, 2018 upon giving the Company a minimum ten-day notice, on January 13, 2016 the Company and the Trust agreed to the full repayment of the loan. Following repayment, the Trust invested $1,110,000 in shares of the Company's common stock and warrants. The de Clara Trust is controlled by Geert Kersten, the Company's Chief Executive Officer and a Director. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 15, 2016 CEL-SCI CORPORATION By:/s/ Patricia B. Prichep ----------------------------------- Patricia B. Prichep, Senior Vice President of Operations